Perflutren lipid microsphere

ApprovedSmall molecule

Perflutren lipid microsphere is one of 121 small molecule programs targeting Kidney Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

120

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Acute Spinal Cord InjuryCompleted

Ischemic StrokeActive, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Acute Spinal Cord InjuryApproved

Completed

Ischemic StrokePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Perflutren lipid microsphere

IImaRx Therapeutics

Approved

1 2

Trodelvy

Gilead

Preclinical

37 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

Adenocard

Astellas

Preclinical

1 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Avastin

Roche

Preclinical

4 9

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Not yet recruiting

Prostate Cancer

NCT06024772

Clinical

Trials by Indication[1]

Kidney Cancer2 trials

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT04021238·25 enrolled

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT03907657·15 enrolled

Ultrasound2 trials

Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT03196076·25 enrolled

Contrast-enhanced Ultrasound of the Kidney

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT02684435·63 enrolled

Prostate Cancer2 trials

Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer

Not yet recruiting·TThomas Jefferson University·Phase 3·NCT06024772·300 enrolled

Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study

Completed·TThomas Jefferson University·Phase 2·NCT02967458·55 enrolled

ESS2 trials

SHAPE for ICP Assessment

Completed·TThomas Jefferson University·Phase 2·NCT06571786·19 enrolled

Microvascular Flow Assessment Repeatability Study: The MARS Study

Terminated·UUniversity of Pennsylvania·N/A·NCT01242020·6 enrolled

Echocardiography1 trial

Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy

Completed·MMayo Clinic·Phase 4·NCT02880137·36 enrolled

5 more indications

Ischemic stroke1 trial

Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke

Terminated·IImaRx Therapeutics·Phase 1/2·NCT00507806

Breast Cancer1 trial

Diagnostic Study of Early Breast Cancer Using Ultrasound

Terminated·SSunnybrook Health Sciences Centre·N/A·NCT01391039·12 enrolled

Ablation1 trial

Contrast ICE for Myocardial Scar in VT Ablations

Completed·WWeill Medical College of Cornell University·N/A·NCT03212326·24 enrolled

Menopausal Women1 trial

A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease

Completed·LLantheus Medical Imaging·Phase 4·NCT00162370·400 enrolled

Acute Spinal Cord Injury1 trial

Utilizing Contrast-enhanced Ultrasound (CEUS) to Assess Critically Hypo Perfused Spinal Cord Tissue After Injury

Completed·UUniversity of Washington·Approved·NCT04056988·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Perflutren lipid microsphere. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Perflutren lipid microsphere compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Perflutren lipid microsphere. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImaRx Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IImaRx Therapeutics

Perflutren lipid microsphere

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Kidney Cancer2 trials

Ultrasound2 trials

Prostate Cancer2 trials

ESS2 trials

Echocardiography1 trial

Ischemic stroke1 trial

Breast Cancer1 trial

Ablation1 trial

Menopausal Women1 trial

Acute Spinal Cord Injury1 trial

References

Drug Info

Quick Facts

Related News